ライフサイエンスコーパス: misoprostol

1 l infusion of a prostaglandin E(1) analogue (misoprostol).

2 of participants chose home administration of misoprostol.

3 was stimulated chemokinetically by PGE2 and misoprostol.

4 oxytocin would be preferred over sublingual misoprostol.

5 one followed 24 to 48 hours later by vaginal misoprostol.

6 nts or the synthetic prostaglandin analogue, misoprostol.

7 c and then chose whether to take 400 mg oral misoprostol 2 days later either at home or in the clinic

8 to receive labour induction with either oral misoprostol 25 mug every 2 h (maximum of 12 doses) or a

9 one, 600 mg orally, followed 2 days later by misoprostol, 400 microg orally (within 49 days from last

10 Misoprostol 600 microg is inferior to oxytocin 10 IU for

11 Of the 491 women assigned to receive misoprostol, 71 percent had complete expulsion by day 3

12 e, 200 mg orally, followed in 1 to 3 days by misoprostol, 800 microg vaginally (up to 63 days).

13 Our results suggest that vaginal misoprostol, 800 microg, can be used from 1 to 3 days af

14 Fifty-five subjects aborted before taking misoprostol, 9 had early surgery, and 103 did not take m

15 Treatment of COX-2(-/-) mice with misoprostol (a PGE(1/2) analog) or beraprost (a PGI(2) a

16 Misoprostol, a PGE1 analog, was developed as an antiulce

17 We aimed to investigate whether oral misoprostol, a potential alternative to oxytocin, could

18 Misoprostol, a potential alternative, is increasingly us

19 Mifepristone-misoprostol abortion, consisting of oral pills, is poten

20 The conventional timing of misoprostol administration after mifepristone for medica

21 2006 Planned Parenthood changed the route of misoprostol administration from vaginal to buccal and re

22 infections were associated with intravaginal misoprostol administration, suggesting that high misopro

23 ce interval [CI], 97%-99%) among those using misoprostol after 1 day, 98% (95% CI, 97%-99%) for those

24 us adverse events occurred: 6 in those using misoprostol after 1 day; 4 in those using it after 2 day

25 1 day, 98% (95% CI, 97%-99%) for those using misoprostol after 2 days, and 96% (95% CI, 95%-97%) amon

26 and 96% (95% CI, 95%-97%) among those using misoprostol after 3 days.

27 cent of the women stated that they would use misoprostol again if the need arose and 83 percent state

28 Misoprostol also reduced TNF-alpha production within the

29 Misoprostol, an effective uterotonic agent with several

30 four E-prostanoid (EP) receptor subtypes and misoprostol, an EP2 and EP4 agonist, increased MUC5AC pr

31 Misoprostol, an EP3 agonist, inhibited glucose-induced i

32 Misoprostol, an FDA-approved EP4 agonist, conferred simi

33 piration to empty the uterus, and the use of misoprostol, an oxytocic agent, have improved the care o

34 tment occurred for 139 (34%) women receiving misoprostol and 123 (31%) receiving oxytocin (RR 1.12, 9

35 initial treatment for 363 (89%) women given misoprostol and 360 (90%) given oxytocin (relative risk

36 dy treatment alone for 440 (90%) women given misoprostol and 468 (96%) given oxytocin (relative risk

37 nt occurred for 147 (30%) of women receiving misoprostol and 83 (17%) receiving oxytocin (RR 1.78, 95

38 s after a change to buccal administration of misoprostol and after initiation of additional infection

39 Community provision of misoprostol and antibiotics to reduce maternal deaths fr

40 o and in vitro experiments demonstrated that misoprostol and beraprost acted directly on hepatic leuk

41 terine hyperstimulation were low in both the misoprostol and Foley catheter groups (two [0.7%] vs one

42 e antigen exposures over a 3-wk period, both misoprostol and its free acid-active metabolite 5C-30695

43 ed in Senegal outside health facilities, and misoprostol and oxytocin delivered via Uniject have been

44 20 (3.6%) and 15 (2.7%) participants in the misoprostol and oxytocin groups, respectively (RR 1.33,

45 432.8 ml (SD 203.5, p<0.001) at 24 h in the misoprostol and oxytocin groups, respectively.

46 Nebulizied solutions of misoprostol and PGE2 effectively blocked the acute bronc

47 ay resistance was 3 and 30 micrograms/ml for misoprostol and PGE2, respectively.

48 d for four hours after the administration of misoprostol and returned on day 15 for final assessment.

49 ion services is changing to include the drug misoprostol and this could reduce the severity of aborti

50 nt change to buccal misoprostol from vaginal misoprostol and to either testing for sexually transmitt

51 icantly by 10(-9) to 10(-7) M PGE2, 10(-6) M misoprostol, and 10(-4) M dibutyryl cyclic AMP, but not

52 ication abortion (such as aspiration, repeat misoprostol, and blood transfusion), frequency of contin

53 ncentration of cyclic AMP ([cAMP]i) by PGE2, misoprostol, and butaprost and of increases in the intra

54 3/EP2/EP4 R-selective agonists M&B 28767 and misoprostol, and EP2 R-selective agonist butaprost but n

55 2, PGE2 methyl ester, misoprostol-free acid, misoprostol, and sulprostone suggested that a negative c

56 exposures in early pregnancy - thalidomide, misoprostol, and valproic acid; maternal rubella infecti

57 ned to self-administer 800 microg of vaginal misoprostol at home 1 (n = 745), 2 (n = 778), or 3 (n =

58 ction rates were higher among those who used misoprostol at home.

59 nist M&B 28767, and the EP2/EP4/EP3R agonist misoprostol but not by the EP1R antagonist SC-19220 or t

60 )-10(-6) M PGE2, sulprostone, M&B 28767, and misoprostol but not with 10(-6) M PGF2alpha, PGD2, PGI2,

61 ssion was confirmed by finding that PGE2 and misoprostol, but not butaprost or sulprostone, evoked in

62 sess whether oxytocin augmentation following misoprostol can be replaced by regular doses of oral mis

63 nge from vaginal to buccal administration of misoprostol combined with routine administration of anti

64 prostol administration, suggesting that high misoprostol concentrations within the uterus impair immu

65 shelf life outside the cold chain, mean that misoprostol could be more appropriate for community-leve

66 Subcutaneous injection of the PGE(2) analog misoprostol decreased M-CSFR expression in bone marrow c

67 The intrauterine injection of misoprostol did not enhance mortality from infection by

68 tervention in both periods was an additional misoprostol dose and was most commonly administered to t

69 P2(-/-) mice, subcutaneous administration of misoprostol during sensitization inhibited allergic infl

70 and EP1/3 (sulprostone) mimicked PGE2, while misoprostol (E1-4) actually enhanced the action of CM.

71 Data are also reviewed demonstrating that misoprostol effectively decreased significant poor gastr

72 The effects of non-selective (PGE2 , misoprostol), EP2 -selective (ONO-AE1-259, AH13205, buta

73 Administration of misoprostol exacerbated collagen-induced arthritis (CIA)

74 rotocol for mifepristone, which is used with misoprostol for medication abortion.

75 hat had been included in a previous study of misoprostol for prevention of postpartum haemorrhage wer

76 tition binding with PGE2, PGE2 methyl ester, misoprostol-free acid, misoprostol, and sulprostone sugg

77 gnificantly after the joint change to buccal misoprostol from vaginal misoprostol and to either testi

78 ut clusters were randomly assigned-14 to the misoprostol group and 14 to the oxytocin group.

79 concentrations was 3.5 g/L (SD 16.1) in the misoprostol group and 2.7 g/L (SD 17.8) in the oxytocin

80 Treatment failed in 16 percent of the misoprostol group and 3 percent of the surgical group (a

81 647 women in the misoprostol group and 402 in the oxytocin group received

82 occurred in 163 (28.6%) participants in the misoprostol group and 99 (17.4%) participants in the oxy

83 group) and eight neonatal deaths (n=5 in the misoprostol group and n=3 in the Foley catheter group);

84 Women in the misoprostol group more commonly experienced shivering (R

85 The misoprostol group received treatment on day 1, a second

86 within 24 h was more common in women in the misoprostol group than in the Foley catheter group (172

87 Surgical treatment (for the misoprostol group) or repeated aspiration (for the vacuu

88 In the misoprostol group, 78 percent of the women stated that t

89 Shivering was common in the misoprostol group, and nausea in the oxytocin group.

90 Women taking misoprostol had a higher rate of transitory symptoms of

91 dvantages over other uterotonics, the use of misoprostol has been increasing, especially in resource-

92 Little is known about the effect inhaled misoprostol has on the airway and whether its potential

93 eatment of diabetic mice with the PGE analog misoprostol improved host defense against MRSA skin infe

94 d within 4 hours after the administration of misoprostol in 49 percent of the women and within 24 hou

95 ts of a large U.S. study of mifepristone and misoprostol in women with pregnancies of up to nine week

96 New treatment regimens for decreasing misoprostol-induced toxicity are also reviewed.

97 Misoprostol is a pharmacomimetic of PGE(2), an endogenou

98 Misoprostol is clinically equivalent to oxytocin when us

99 Misoprostol is increasingly used to treat women who have

100 This trial established whether sublingual misoprostol is non-inferior to intravenous oxytocin for

101 i-inflammatory effects suggests that inhaled misoprostol may be an effective treatment for the acute

102 gs in which use of oxytocin is not feasible, misoprostol might be a suitable first-line treatment alt

103 andomly assigned 602 women to induction with misoprostol (n=302) or the Foley catheter (n=300; intent

104 nd were randomly assigned to receive 800 mug misoprostol (n=407) or 40 IU intravenous oxytocin (n=402

105 were randomly assigned to receive 800 microg misoprostol (n=488) or 40 IU intravenous oxytocin (n=490

106 rural India were randomised to receive oral misoprostol (n=812) or placebo (n=808) after delivery.

107 l, 9 had early surgery, and 103 did not take misoprostol on their assigned day.

108 uity Health Projects) to either 600 mug oral misoprostol or 10 IU oxytocin in Uniject (intramuscular)

109 Their place in therapy, compared with use of misoprostol or proton pump inhibitors, is currently emer

110 bortion), the increasingly widespread use of misoprostol outside formal health systems in contexts wh

111 Differences favoring diclofenac + misoprostol over acetaminophen were greater in patients

112 more common when patients took diclofenac + misoprostol (P = 0.046).

113 parative efficacy of oxytocin and sublingual misoprostol, particularly at the recommended dose of 600

114 se complications have been demonstrated with misoprostol, proton pump inhibitors (PPIs) (only documen

115 o simplifications to the French mifepristone-misoprostol regimen in Vietnam and Tunisia.

116 This mifepristone-misoprostol regimen is effective in terminating pregnanc

117 owed by the option of home administration of misoprostol seems feasible.

118 uterine but not the intragastric delivery of misoprostol significantly worsened mortality from C. sor

119 Exposure to a 300 micrograms/ml nebulized misoprostol solution provided significant protection for

120 domized 1,140 women to receive 600 microg of misoprostol sublingually or 10 IU of oxytocin intramuscu

121 In vitro, misoprostol suppressed macrophage TNF-alpha and chemokin

122 Two low-cost interventions-low-dose oral misoprostol tablets and transcervical Foley catheterisat

123 tol can be replaced by regular doses of oral misoprostol tablets.

124 primary outcomes were seen for diclofenac + misoprostol than for acetaminophen (P < 0.001).

125 n pain scores over 6 weeks with diclofenac + misoprostol than with acetaminophen, although patients w

126 09-1.99) were significantly more common with misoprostol than with oxytocin.

127 52-11.8) were significantly more common with misoprostol than with oxytocin.

128 estimulation, draining lymph node cells from misoprostol-treated mice secreted higher levels of IL-17

129 of two groups, 75 mg diclofenac + 200 microg misoprostol twice daily or 1,000 mg acetaminophen 4 time

130 00 mg of mifepristone and then 400 microg of misoprostol two days later to 2121 women seeking termina

131 mends use of oxytocin for prevention of PPH, misoprostol use is increasingly common owing to advantag

132 f early pregnancy failure with 800 microg of misoprostol vaginally is a safe and acceptable approach,

133 e randomly assigned to receive 800 microg of misoprostol vaginally or to undergo vacuum aspiration (s

134 The PGE2 analog misoprostol was administered during sensitization in bot

135 A second dose of misoprostol was administered if the abortion was not com

136 on after medical abortion during a time when misoprostol was administered vaginally (through March 20

137 Misoprostol was also associated with a decrease in mean

138 Oral misoprostol was associated with a significant reduction

139 Oral misoprostol was associated with significant decreases in

140 The effect of the stable PGE analog misoprostol was evaluated in a murine model of rheumatoi

141 INTERPRETATION: Oral misoprostol was more effective than transcervical Foley

142 Diclofenac + misoprostol was rated as "better" or "much better" by 57

143 oglobin concentrations, neither oxytocin nor misoprostol was significantly better than the other, and

144 This trial established whether sublingual misoprostol was similarly efficacious to intravenous oxy

145 ifepristone (also known as RU-486) used with misoprostol were reported.

146 ologic agents, such as PGE2, PGF2 alpha, and misoprostol, were applied topically to the eye.

147 These immunosuppressive effects of misoprostol, which were not shared by mifepristone, corr

148 ts CML LSCs and that the combination of PGE1/misoprostol with conventional tyrosine-kinase inhibitors

149 Clinical equivalence of misoprostol would be accepted if the upper bound of the